Recommendations for COVID-19

Is CBTH for me?

CBTH provides the development of computational biology skills for scholars who want to build successful careers in hematology research.

Is TRTH for me?

Please see the eligibility criteria in the dropdown menu below.

Is CRTH for me?

Eligibility
Applicant must be a trainee or junior faculty and hold an MD or MD/PhD 
Applicant must be actively employed in a hematology or hematology-related research environment 
The applicant must be an EHA member or EHA Guest at the time of application submission…

Faculty details

Welcome to the faculty details page. On this page you can find instructions for the speakers and chairs of the congress:

You can download the PowerPoint Template here. If you use your own template, please use a 16x9 format.

5th European CAR T-cell Meeting

The European Hematology Association (EHA) and the EBMT are excited to announce the 5th edition of the jointly organized European CAR T-cell Meeting.

Appointment of new EHA Managing Director

The Hague (Netherlands), January 16, 2023. The European Hematology Association (EHA) is pleased to welcome its new Managing Director, Ignacio Quiles Lara, who took up the post on January 9.

Executive office

The EHA Board and its committees are supported by the Executive Office. An international team of staff members work in a dynamic, result-driven and open environment and takes pride in serving the association in an efficient manner.

King Baudouin Foundation – Calls with a relevance to hematology

The King Baudouin Foundation is an actor for change and innovation, serving the public interest and increasing social cohesion. It endeavours to maximise its impact through capacity building among organisations and people who contribute to building a better society.

T2EVOLVE: breakthrough alliance boosting Europe to the forefront of cancer immunotherapy

This press release is originally found here: http://prn. to/2YF7Js3

THE HAGUE, Netherlands, Feb. 3, 2021 /PRNewswire/ -- T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union's Innovative Medicines Initiative (IMI).